James Brenton publications

High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer
Chin SF;Teschendorff AE;Marioni JC;Wang Y;Barbosa-Morais NL;Thorne NP;Costa JL;Pinder SE;De Wiel MAV;Green AR;Ellis IO;Porter PL;Tavare S;Brenton JD;Ylstra B;Caldas C
Genome Biol 2007; 8 (10):R215.

The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel
Ahmed AA;Mills AD;Ibrahim AEK;Temple J;Blenkiron C;Vias M;Massie CE;Iyer NG;McGeoch A;Crawford R;Nicke B;Downward J;Swanton C;Bell SD;Earl HM;Laskey RA;Caldas C;Brenton JD
Cancer Cell 2007; 12 (6):514-527.

High resolution melting for mutation scanning of TP53 exons 5-8
Krypuy M;Ahmed AA;Etemadmoghadam D;Hyland SJ;deFazio A;Fox SB;Brenton JD;Bowtell DD;Dobrovic A;Australian Ovarian Canc Study Grp
BMC Cancer 2007; 7 ():168.

BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappa B inhibition of apoptosis in breast cancer cell lines
Naderi A;Teschendorff AE;Beigel J;Cariati M;Ellis IO;Brenton JD;Caldas C
Cancer Res 2007; 67 (14):6725-6736.

Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs
Swanton C;Marani M;Pardo O;Warne PH;Kelly G;Sahai E;Elustondo F;Chang J;Temple J;Ahmed AA;Brenton JD;Downward J;Nicke B
Cancer Cell 2007; 11 (6):498-512.

Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers
Chin SF;Wang Y;Thorne NP;Teschendorff AE;Pinder SE;Vias M;Naderi A;Roberts I;Barbosa-Morais NL;Garcia MJ;Iyer NG;Kranjac T;Robertson JFR;Aparicio S;Tavare S;Ellis I;Brenton JD;Caldas C
Oncogene 2007; 26 (13):1959-1970.

A gene-expression signature to predict survival in breast cancer across independent data sets
Naderi A;Teschendorff AE;Barbosa-Morais NI;Pinder SE;Green AR;Powe DG;Robertson JFR;Aparicio S;Ellis IO;Brenton JD;Caldas C
Oncogene 2007; 26 (10):1507-1516.

Genomic analysis of the 8p11-12 amplicon in familial breast cancer
Melchor L;Garcia MJ;Honrado E;Pole JCM;Alvarez S;Edwards PAW;CaldaS C;Brenton JD;Benitez J
Int J Cancer 2007; 120 (3):714-717.

MMASS: an optimized array-based method for assessing CpG island methylation
Ibrahim AEK;Thorne NP;Baird K;Barbosa-Morais NL;Tavare S;Collins VP;Wyllie AH;Arends MJ;Brenton JD
Nucleic Acids Res 2006; 34 (20):e136.

A consensus prognostic gene expression classifier for ER positive breast cancer
Teschendorff AE;Naderi A;Barbosa-Morais NL;Pinder SE;Ellis IO;Aparicio S;Brenton JD;Caldas C
Genome Biol 2006; 7 (10):R101.

Metabolic consequences of p300 gene deletion in human colon cancer cells
Bundy JG;Iyer NG;Gentile MS;Hu DE;Kettunen M;Maia AT;Thorne NP;Brenton JD;Caldas C;Brindle KM
Cancer Res 2006; 66 (15):7606-7614.

Differential expression of selected histone modifier genes in human solid cancers
Ozdag H;Teschendorff AE;Ahmed AA;Hyland SJ;Blenkiron C;Bobrow L;Veerakumarasivam A;Burtt G;Subkhankulova T;Arends MJ;Collins VP;Bowtell D;Kouzarides T;Brenton JD;Caldas C
BMC Genomics 2006; 7 ():90.

Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition
Krubasik D;Iyer NG;English WR;Ahmed AA;Vias M;Roskelley C;Brenton JD;Caldas C;Murphy G
Br J Cancer 2006; 94 (9):1326-1332.

Expression microarray reproducibility is improved by optimising purification steps in RNA amplification and labelling
Naderi A;Ahmed AA;Barbosa-Morais NL;Aparicio S;Brenton JD;Caldas C
BMC Genomics 2004; 5 ():9.

Microarray segmentation methods significantly influence data precision
Ahmed AA;Vias M;Iyer NG;Caldas C;Brenton JD
Nucleic Acids Res 2004; 32 (5):e5.

Predictive cancer genomics - what do we need?
Brenton JD;Caldas C
Lancet 2003; 362 (9381):340-341.

Novel conserved elements upstream of the H19 gene are transcribed and act as mesodermal enhancers
Drewell RA;Arney KL;Arima T;Barton SC;Brenton JD;Surani MA
Development 2002; 129 (5):1205-1213.